Treating dyslipidaemia in primary care
- 25 November 2000
- Vol. 321 (7272), 1299-1300
- https://doi.org/10.1136/bmj.321.7272.1299
Abstract
Papers p 1322 Standards three and four of the NHS's National Service Framework for Coronary Heart Disease require primary care teams to identify and modify risk factors in patients who have a greater than 30% risk of developing heart disease over 10 years; they must also offer advice and treatment to all patients with established coronary artery disease to help them reduce their risks.1 Yet the study published by Primatesta and Poulter this week (p 1322) found that less than one third of patients in England who have a history of coronary heart disease or stroke receive lipid lowering treatment, and that recently recommended targets for cholesterol concentrations were reached by only about 1 in 10 of those who were eligible for treatment.2 Primatesta and Poulter's findings are in accordance with those of other studies.3–5 Why are so few patients receiving lipid lowering treatment? The consensus that cholesterol is an important reversible risk factor for coronary heart disease was reached only comparatively recently as a result of studies published in 1994 and 1995. 6 7 In the United Kingdom, extra resources to fund this additional treatment have not been provided. At the recent meeting of the European Society of Cardiology (Amsterdam, August 2000) unpublished data were …Keywords
This publication has 12 references indexed in Scilit:
- Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional surveyBMJ, 2000
- AN ASSESSMENT OF THE EFFICACY OF ATORVASTATIN IN ACHIEVING LDL CHOLESTEROL TARGET LEVELS IN PATIENTS WITH CORONARY HEART DISEASE: A GENERAL PRACTICE STUDYInternational Journal Of Clinical Practice, 1999
- Persistence of Use of Lipid-Lowering MedicationsJAMA, 1998
- EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal resultsEuropean Heart Journal, 1997
- A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).Heart, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994
- Might treatment of hypercholesterolaemia increase non-cardiac mortality?The Lancet, 1991
- THE INVERSE CARE LAWThe Lancet, 1971